{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T19:53:03Z","timestamp":1789069983234,"version":"build-2803163510"},"reference-count":51,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2012,4]]},"DOI":"10.1097\/cad.0b013e32834f6ea8","type":"journal-article","created":{"date-parts":[[2011,12,24]],"date-time":"2011-12-24T05:20:09Z","timestamp":1324704009000},"page":"370-379","source":"Crossref","is-referenced-by-count":79,"title":["Antiproliferative effects of artemisinin on human breast cancer cells requires the downregulated expression of the E2F1 transcription factor and loss of E2F1-target cell cycle genes"],"prefix":"10.1097","volume":"23","author":[{"given":"Antony S.","family":"Tin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shyam N.","family":"Sundar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kalvin Q.","family":"Tran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna H.","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin M.","family":"Poindexter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gary L.","family":"Firestone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-3-20210227","doi-asserted-by":"crossref","first-page":"303","DOI":"10.3322\/caac.20029","article-title":"New molecular classifications of breast cancer.","volume":"59","author":"Cianfrocca","year":"2009","journal-title":"CA Cancer J Clin"},{"key":"R2-3-20210227","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1038\/35021093","article-title":"Molecular portraits of human breast tumours.","volume":"406","author":"Perou","year":"2000","journal-title":"Nature"},{"key":"R3-3-20210227","first-page":"105","article-title":"Variant human breast tumor estrogen receptor with constitutive transcriptional activity.","volume":"51","author":"Fuqua","year":"1991","journal-title":"Cancer Res"},{"key":"R4-3-20210227","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1016\/0960-0760(90)90416-I","article-title":"Transition of human breast cancer cells from an oestrogen responsive to unresponsive state.","volume":"37","author":"Darbre","year":"1990","journal-title":"J Steroid Biochem Mol Biol"},{"key":"R5-3-20210227","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1038\/nrc2212","article-title":"Molecular heterogeneity of breast carcinomas and the cancer stem cell hypothesis.","volume":"7","author":"Stingl","year":"2007","journal-title":"Nat Rev Cancer"},{"key":"R6-3-20210227","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.2174\/138955709789055207","article-title":"Recent advances in selective estrogen receptor modulators for breast cancer.","volume":"9","author":"Wang","year":"2009","journal-title":"Mini Rev Med Chem"},{"key":"R7-3-20210227","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1097\/COC.0b013e31816d9171","article-title":"Safety of adjuvant endocrine therapy in postmenopausal women with breast cancer.","volume":"31","author":"Abdulhaq","year":"2008","journal-title":"Am J Clin Oncol"},{"key":"R8-3-20210227","doi-asserted-by":"crossref","first-page":"2081","DOI":"10.1517\/14656560903117309","article-title":"Pharmacotherapy of triple-negative breast cancer.","volume":"10","author":"Arslan","year":"2009","journal-title":"Expert Opin Pharmacother"},{"key":"R9-3-20210227","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1016\/j.ctrv.2009.04.002","article-title":"Management of primary and advanced breast cancer in older unfit patients (medical treatment).","volume":"35","author":"Aapro","year":"2009","journal-title":"Cancer Treat Rev"},{"key":"R10-3-20210227","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1158\/1940-6207.CAPR-08-0223","article-title":"Development of dietary phytochemical chemopreventive agents: biomarkers and choice of dose for early clinical trials.","volume":"2","author":"Scott","year":"2009","journal-title":"Cancer Prev Res (Phila)"},{"key":"R11-3-20210227","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1186\/1475-2875-10-203","article-title":"Changing patterns of malaria during 1996-2010 in an area of moderate transmission in Southern Senegal.","volume":"10","author":"Brasseur","year":"2011","journal-title":"Malar J"},{"key":"R12-3-20210227","doi-asserted-by":"crossref","first-page":"561","DOI":"10.4065\/mcp.2011.0203","article-title":"Antiparasitic therapy.","volume":"86","author":"Kappagoda","year":"2011","journal-title":"Mayo Clin Proc"},{"key":"R13-3-20210227","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1016\/S0020-7519(02)00194-7","article-title":"Artemisinin: mechanisms of action, resistance and toxicity.","volume":"32","author":"Meshnick","year":"2002","journal-title":"Int J Parasitol"},{"key":"R14-3-20210227","first-page":"767","article-title":"The anti-malarial artesunate is also active against cancer.","volume":"18","author":"Efferth","year":"2001","journal-title":"Int J Oncol"},{"key":"R15-3-20210227","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1186\/1749-8546-6-27","article-title":"Anti-cancer natural products isolated from chinese medicinal herbs.","volume":"6","author":"Tan","year":"2011","journal-title":"Chin Med"},{"key":"R16-3-20210227","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.1002\/ijc.24496","article-title":"Artemisinin dimer anticancer activity correlates with heme-catalyzed reactive oxygen species generation and endoplasmic reticulum stress induction.","volume":"125","author":"Stockwin","year":"2009","journal-title":"Int J Cancer"},{"key":"R17-3-20210227","doi-asserted-by":"crossref","first-page":"e32","DOI":"10.1017\/S1462399409001239","article-title":"Anticancer activities of artemisinin and its bioactive derivatives.","volume":"11","author":"Firestone","year":"2009","journal-title":"Expert Rev Mol Med"},{"key":"R18-3-20210227","doi-asserted-by":"crossref","first-page":"407","DOI":"10.2174\/138945006776359412","article-title":"Molecular pharmacology and pharmacogenomics of artemisinin and its derivatives in cancer cells.","volume":"7","author":"Efferth","year":"2006","journal-title":"Curr Drug Targets"},{"key":"R19-3-20210227","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1055\/s-2007-967138","article-title":"Willmar Schwabe Award 2006: antiplasmodial and antitumor activity of artemisinin: from bench to bedside.","volume":"73","author":"Efferth","year":"2007","journal-title":"Planta Med"},{"key":"R20-3-20210227","doi-asserted-by":"crossref","first-page":"2359","DOI":"10.1016\/j.bcp.2004.08.021","article-title":"Inhibition of angiogenesis in vivo and growth of Kaposis sarcoma xenograft tumors by the anti-malarial artesunate.","volume":"68","author":"DellEva","year":"2004","journal-title":"Biochem Pharmacol"},{"key":"R21-3-20210227","first-page":"729","article-title":"In-vitro tests on Philippine isolates of Plasmodium falciparum against four standard antimalarials and four qinghaosu derivatives.","volume":"72","author":"Bustos","year":"1994","journal-title":"Bull World Health Organ"},{"key":"R22-3-20210227","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/0166-6851(91)90062-B","article-title":"Artemisinin (qinghaosu): the role of intracellular hemin in its mechanism of antimalarial action.","volume":"49","author":"Meshnick","year":"1991","journal-title":"Mol Biochem Parasitol"},{"key":"R24-3-20210227","doi-asserted-by":"crossref","first-page":"5519","DOI":"10.1158\/1078-0432.CCR-08-0197","article-title":"Experimental therapy of hepatoma with artemisinin and its derivatives: in vitro and in vivo activity, chemosensitization, and mechanisms of action.","volume":"14","author":"Hou","year":"2008","journal-title":"Clin Cancer Res"},{"key":"R25-3-20210227","doi-asserted-by":"crossref","first-page":"2203","DOI":"10.1074\/jbc.M804491200","article-title":"Artemisinin blocks prostate cancer growth and cell cycle progression by disrupting Sp1 interactions with the cyclin-dependent kinase-4 (CDK4) promoter and inhibiting CDK4 gene expression.","volume":"284","author":"Willoughby","year":"2009","journal-title":"J Biol Chem"},{"key":"R26-3-20210227","doi-asserted-by":"crossref","first-page":"2252","DOI":"10.1093\/carcin\/bgn214","article-title":"Artemisinin selectively decreases functional levels of estrogen receptor-alpha and ablates estrogen-induced proliferation in human breast cancer cells.","volume":"29","author":"Sundar","year":"2008","journal-title":"Carcinogenesis"},{"key":"R27-3-20210227","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/j.cbi.2010.05.015","article-title":"1-Benzyl-indole-3-carbinol is a novel indole-3-carbinol derivative with significantly enhanced potency of anti-proliferative and anti-estrogenic properties in human breast cancer cells.","volume":"186","author":"Nguyen","year":"2010","journal-title":"Chem Biol Interact"},{"key":"R28-3-20210227","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1007\/BF00300234","article-title":"Determination of subcutaneous tumor size in athymic (nude) mice.","volume":"24","author":"Tomayko","year":"1989","journal-title":"Cancer Chemother Pharmacol"},{"key":"R29-3-20210227","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1023\/B:BREA.0000014042.54925.cc","article-title":"Relevance of breast cancer cell lines as models for breast tumours: an update.","volume":"83","author":"Lacroix","year":"2004","journal-title":"Breast Cancer Res Treat"},{"key":"R30-3-20210227","first-page":"3071","article-title":"MCF-7: the first hormone-responsive breast cancer cell line.","volume":"57","author":"Levenson","year":"1997","journal-title":"Cancer Res"},{"key":"R31-3-20210227","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/0304-3835(94)03716-V","article-title":"Selective cancer cell cytotoxicity from exposure to dihydroartemisinin and holotransferrin.","volume":"91","author":"Lai","year":"1995","journal-title":"Cancer Lett"},{"key":"R32-3-20210227","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1007\/s00296-009-1218-7","article-title":"The anti-malaria agent artesunate inhibits expression of vascular endothelial growth factor and hypoxia-inducible factor-1alpha in human rheumatoid arthritis fibroblast-like synoviocyte.","volume":"31","author":"He","year":"2011","journal-title":"Rheumatol Int"},{"key":"R33-3-20210227","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1007\/s00280-003-0751-4","article-title":"Antimalarial dihydroartemisinin also inhibits angiogenesis.","volume":"53","author":"Chen","year":"2004","journal-title":"Cancer Chemother Pharmacol"},{"key":"R34-3-20210227","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1021\/jm0303711","article-title":"Anticancer and antimalarial efficacy and safety of artemisinin-derived trioxane dimers in rodents.","volume":"47","author":"Posner","year":"2004","journal-title":"J Med Chem"},{"key":"R35-3-20210227","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1124\/mol.64.2.382","article-title":"Molecular modes of action of artesunate in tumor cell lines.","volume":"64","author":"Efferth","year":"2003","journal-title":"Mol Pharmacol"},{"key":"R37-3-20210227","doi-asserted-by":"crossref","first-page":"7632","DOI":"10.1038\/sj.onc.1206840","article-title":"Distinct recruitment of E2F family members to specific E2F-binding sites mediates activation and repression of the E2F1 promoter.","volume":"22","author":"Araki","year":"2003","journal-title":"Oncogene"},{"key":"R38-3-20210227","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1007\/s00428-005-0146-5","article-title":"Expression of cyclin-dependent kinases and CDC25a phosphatase is related with recurrences and survival in women with peri- and post-menopausal breast cancer.","volume":"448","author":"Bonin","year":"2006","journal-title":"Virchows Arch"},{"key":"R40-3-20210227","doi-asserted-by":"crossref","first-page":"8756","DOI":"10.1074\/jbc.M407957200","article-title":"Indole-3-carbinol (I3C) inhibits cyclin-dependent kinase-2 function in human breast cancer cells by regulating the size distribution, associated cyclin E forms, and subcellular localization of the CDK2 protein complex.","volume":"280","author":"Garcia","year":"2005","journal-title":"J Biol Chem"},{"key":"R41-3-20210227","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1021\/jf802881d","article-title":"Indole-3-carbinol inhibits Sp1-induced matrix metalloproteinase-2 expression to attenuate migration and invasion of breast cancer cells.","volume":"57","author":"Hung","year":"2009","journal-title":"J Agric Food Chem"},{"key":"R42-3-20210227","doi-asserted-by":"crossref","first-page":"3319","DOI":"10.1158\/1078-0432.CCR-06-0225","article-title":"Which cyclin E prevails as prognostic marker for breast cancer Results from a retrospective study involving 635 lymph node-negative breast cancer patients.","volume":"12","author":"Sieuwerts","year":"2006","journal-title":"Clin Cancer Res"},{"key":"R43-3-20210227","first-page":"395","article-title":"E2F-1: a proliferative marker of breast neoplasia.","volume":"9","author":"Zhang","year":"2000","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"R44-3-20210227","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1007\/s00432-009-0731-0","article-title":"Growth inhibitory effects of dihydroartemisinin on pancreatic cancer cells: involvement of cell cycle arrest and inactivation of nuclear factor-kappaB.","volume":"136","author":"Chen","year":"2010","journal-title":"J Cancer Res Clin Oncol"},{"key":"R45-3-20210227","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1124\/mol.108.045286","article-title":"Activation of nuclear factor-kappa B pathway by simvastatin and RhoA silencing increases doxorubicin cytotoxicity in human colon cancer HT29 cells.","volume":"74","author":"Riganti","year":"2008","journal-title":"Mol Pharmacol"},{"key":"R46-3-20210227","doi-asserted-by":"crossref","first-page":"233","DOI":"10.3892\/ijmm.2010.580","article-title":"The anti-malarial artemisinin inhibits pro-inflammatory cytokines via the NF-kappaB canonical signaling pathway in PMA-induced THP-1 monocytes.","volume":"27","author":"Wang","year":"2011","journal-title":"Int J Mol Med"},{"key":"R47-3-20210227","first-page":"337","article-title":"Effects of artesunate on cytokinesis and GM cell cycle progression of tumour cells and budding yeast.","volume":"7","author":"Steinbruck","year":"2010","journal-title":"Cancer Genomics Proteomics"},{"key":"R48-3-20210227","doi-asserted-by":"crossref","first-page":"591","DOI":"10.3736\/jcim20080609","article-title":"Artesunate induces prostate cancer cell line PC-3 differentiation and cell cycle arrest.","volume":"6","author":"Huang","year":"2008","journal-title":"Zhong Xi Yi Jie He Xue Bao"},{"key":"R49-3-20210227","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1007\/s10585-011-9405-9","article-title":"Migration of MDA-MB-231 breast cancer cells depends on the availability of exogenous lipids and cholesterol esterification.","volume":"28","author":"Antalis","year":"2011","journal-title":"Clin Exp Metastasis"},{"key":"R50-3-20210227","doi-asserted-by":"crossref","first-page":"32260","DOI":"10.1074\/jbc.272.51.32260","article-title":"Role of estrogen receptor gene demethylation and DNA methyltransferase. DNA adduct formation in 5-aza-2-deoxycytidine-induced cytotoxicity in human breast cancer cells.","volume":"272","author":"Ferguson","year":"1997","journal-title":"J Biol Chem"},{"key":"R51-3-20210227","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1007\/s10549-005-9077-8","article-title":"High-resolution mapping of molecular events associated with immortalization, transformation, and progression to breast cancer in the MCF10 model.","volume":"96","author":"Worsham","year":"2006","journal-title":"Breast Cancer Res Treat"},{"key":"R52-3-20210227","first-page":"6075","article-title":"Isolation and characterization of a spontaneously immortalized human breast epithelial cell line, MCF-10.","volume":"50","author":"Soule","year":"1990","journal-title":"Cancer Res"},{"key":"R53-3-20210227","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1016\/j.lfs.2004.08.020","article-title":"Effects of artemisinin-tagged holotransferrin on cancer cells.","volume":"76","author":"Lai","year":"2005","journal-title":"Life Sci"},{"key":"R54-3-20210227","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1111\/j.1745-7254.2007.00612.x","article-title":"Dihydroartemisinin is an inhibitor of ovarian cancer cell growth.","volume":"28","author":"Jiao","year":"2007","journal-title":"Acta Pharmacol Sin"}],"container-title":["Anti-Cancer Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/CAD.0b013e32834f6ea8","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T20:30:43Z","timestamp":1786048243000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/00001813-201204000-00003"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,4]]},"references-count":51,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2012]]}},"URL":"https:\/\/doi.org\/10.1097\/cad.0b013e32834f6ea8","relation":{},"ISSN":["0959-4973"],"issn-type":[{"value":"0959-4973","type":"print"}],"subject":[],"published":{"date-parts":[[2012,4]]}}}